


EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY

Health systems, medical products and innovation Medicines: policy, authorisation and monitoring



## <u>Subject</u>: Repurposing of established medicines/active substances Agenda item 3

The issue of repurposing of established medicines had been discussed in previous meetings of the Safe and Timely Access to Medicines for Patients (STAMP) Expert Group. During the 10<sup>th</sup> meeting on 3 December 2018 there was a discussion on the proposal for a framework for repurposing existing medicines which had been developed by a working group including representatives from Member States and stakeholders from industry, not-for-profit, patient, healthcare and payer representative organisations. The STAMP agreed that the proposal for the framework should be further developed within the working group.

The group has completed the following activities:

- Updated the document outlining the proposed repurposing framework including the objectives and deliverables of the pilot of the framework, a proposal for a 'repurposing monitoring board' to monitor the pilot and an initial list of resources/sources of information for Champions
- Considered potential candidate molecules for a pilot of the proposed repurposing framework
- Prepared an overview of the aims of objectives of the EU Coordination and Support Action - STARS: Strengthening training of academia in regulatory sciences & supporting regulatory scientific advice

The STAMP participants are asked to consider the documents which have been prepared by the working group, specifically considering the following points:

1. Is the suggested framework clear? Are there aspects of the proposed framework that need to be clarified before the start of the possible pilot projects?

- 2. Are the objectives and deliverables of the pilot of the repurposing framework appropriate? Are there any gaps?
- 3. The proposal for a 'repurposing monitoring board', is this supported and are the suggested role and activities considered appropriate and complete? Who should be represented on the board?
- 4. Regarding the list of useful resources etc., are there other resources and contacts that should be included in the list?
- 5. The suggested candidate molecules/medicines, are there any which are not appropriate to be included in the pilot?
- 6. What should be the process to identify other candidate molecules?